Published: September 27, 2021 Abstract: Introduction: Cannabigerol (CBG), and its precursor before decarboxylation, cannabigerolic acid is sometimes labeled the ‘‘mother of all cannabinoids.’’ The purpose of the present study was to investigate reasons for use and...
Research
cannabigerol
Meta-Analysis of Cannabigerol Effects on Breast Cancer Tissue Cells
Published: May 4, 2021 Abstract: Cannabigerol (CBG) is one of over 120 cannabinoids known that is produced by the Cannabis sativa plant and has become of recent therapeutic interest. Cannabinoids target primarily cannabinoid receptors 1 and 2 (CBR1/CBR2) and form...
Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis derived non-psychotropic cannabinoid
Published: September 30, 2014 Abstract: Cannabigerol (CBG) is a safe non-psychotropic Cannabis-derived cannabinoid (CB), which interacts with specific targets involved in carcinogenesis. Specifically, CBG potently blocks transient receptor potential (TRP) M8 (TRPM8),...
Cannabinoids in Breast Cancer: Differential Susceptibility According to Subtype
Published: December 28, 2021 Abstract: Although cannabinoids have been used for centuries for diverse pathological conditions, recently, their clinical interest and application have emerged due to their diverse pharmacological properties. Indeed, it is well...
Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma
Published: February 5, 2021 Abstract: Glioblastoma is the most aggressive cancer among primary brain tumors. As with other cancers, the incidence of glioblastoma is increasing; despite modern therapies, the overall mean survival of patients' post-diagnosis averages...
Cannabinoid Decarboxylation: A Comparative Kinetic Study
Published: October 20, 2020 Abstract: Cannabinoids like Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabigerol (CBG) are considered the main active components in Cannabis sativa L. and are obtained through the decarboxylation of their acid analogues (THCA,...
Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1–CB2 Heteroreceptor Complexes
Published: June 21, 2018 Abstract: Cannabigerol (CBG) is one of the major phytocannabinoids present in Cannabis sativa L. that is attracting pharmacological interest because it is non-psychotropic and is abundant in some industrial hemp varieties. The aim of this work...
Cannabigerol Prevents Quorum Sensing and Biofilm Formation of Vibrio Harveyi
Published: May 7, 2021 Abstract: Cannabigerol (CBG) is a non-psychoactive cannabinoid naturally present in trace amounts in the Cannabis plant. So far, CBG has been shown to exert diverse activities in eukaryotes. However, much less is known about its effects on...
Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood–Brain Barrier Under Ischemic Conditions
Published: August 5, 2021 Abstract: Background and Objectives: Preclinical studies have shown cannabidiol is protective in models of ischemic stroke. Based on results from our recent systematic review, we investigated the effects of two promising neuroprotective...
Cannabinoid CB2 Receptors are Involved in the Protection of RAW264.7 Macrophages Against the Oxidative Stress: An in Vitro Study
Published: January 23, 2017 Abstract: Research in the last decades has widely investigated the anti-oxidant properties of natural products as a therapeutic approach for the prevention and the treatment of oxidative-stress related disorders. In this context, several...